Correction to Lancet Diabetes Endocrinol 2024; 12: 523–34

Abstract

Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol 2024; 12: 523–34—In table 1, the number of participants in the placebo group listed as currently using tenofovir alafenamide has been corrected to 37 (69%). In the second paragraph of the results section, the fourth sentence has been corrected to, “80 (74%) of participants were on tenofovir alafenamide; 66 (61%) participants were on INSTI and tenofovir alafenamide.” In table 2, the subheadings have been corrected to: ln fasting insulin, uIU/mL; ln fasting HOMA-IR; In high-density lipoprotein cholesterol, mg/dL; In very low-density lipoprotein cholesterol, mg/dL; and ln triglycerides, mg/dL. Also in table 2, for the subheading ln atherosclerotic cardiovascular disease risk estimate; the β* value has been corrected to −0·39, the SE to 0·18, the 95% CI of β to −0·74 to −0·05, the p value to 0·0264‡, and the % change† to –32·6%. In the seventh paragraph of the results section, the second sentence has been corrected to, “Diastolic blood pressure, heart rate, total cholesterol, low-density lipoprotein cholesterol, caloric intake, and physical activity did not show any statistically significant changes.” The last two sentences of the seventh paragraph of the discussion have been removed. These changes have been made to the online version as of Feb 21, 2025.